Although alternative splicing (AS) has emerged as a critical regulatory mechanism in cancer, its role in EC progression and chemoresistance remains poorly understood.[18, 27] In this study, we identify SF3A3 as a key oncogenic splicing factor in EC and demonstrate that its overexpression drives tumor growth, enhances cisplatin resistance, and suppresses apoptosis. The gene discussed is SF3A3; the disease is cancer.